Thomas Crom, Chief Financial Officer of Umbra Applied Technologies Group, Inc. recently stated, "The UAT Biotech division is expected to drive revenues for the next seven to eight months with additional divisions coming on line mid-2018. UAT is currently reviewing several acquisitions so I would expect an expansion of revenues and assets in the near future."